Treace Medical Concepts, Inc. (NASDAQ:TMCI) VP Aaron Berutti Buys 1,825 Shares of Stock

Treace Medical Concepts, Inc. (NASDAQ:TMCIGet Rating) VP Aaron Berutti purchased 1,825 shares of the company’s stock in a transaction that occurred on Monday, November 21st. The shares were bought at an average cost of $21.86 per share, with a total value of $39,894.50. Following the transaction, the vice president now directly owns 13,775 shares of the company’s stock, valued at approximately $301,121.50. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Treace Medical Concepts Stock Performance

Treace Medical Concepts stock opened at $21.77 on Tuesday. Treace Medical Concepts, Inc. has a 52-week low of $12.48 and a 52-week high of $25.02. The firm has a fifty day moving average of $22.79 and a 200-day moving average of $18.98. The company has a debt-to-equity ratio of 0.85, a current ratio of 5.66 and a quick ratio of 4.92.

Treace Medical Concepts (NASDAQ:TMCIGet Rating) last released its quarterly earnings data on Tuesday, November 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.06. Treace Medical Concepts had a negative net margin of 35.87% and a negative return on equity of 51.67%. The company had revenue of $33.06 million during the quarter, compared to analyst estimates of $30.10 million. As a group, analysts predict that Treace Medical Concepts, Inc. will post -0.75 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on TMCI shares. BTIG Research upped their price target on shares of Treace Medical Concepts to $29.00 in a research report on Tuesday, November 15th. Morgan Stanley upped their price target on shares of Treace Medical Concepts from $23.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 11th. Finally, Stifel Nicolaus upped their price target on shares of Treace Medical Concepts from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, September 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Newbridge Financial Services Group Inc. boosted its stake in shares of Treace Medical Concepts by 28.7% in the third quarter. Newbridge Financial Services Group Inc. now owns 2,454 shares of the company’s stock valued at $54,000 after purchasing an additional 547 shares during the period. UBS Group AG boosted its stake in shares of Treace Medical Concepts by 79.1% in the third quarter. UBS Group AG now owns 1,442 shares of the company’s stock valued at $32,000 after purchasing an additional 637 shares during the period. American International Group Inc. boosted its stake in shares of Treace Medical Concepts by 4.5% in the second quarter. American International Group Inc. now owns 15,610 shares of the company’s stock valued at $224,000 after purchasing an additional 676 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Treace Medical Concepts by 35.2% in the third quarter. Tower Research Capital LLC TRC now owns 5,363 shares of the company’s stock valued at $118,000 after purchasing an additional 1,397 shares during the period. Finally, CWM LLC purchased a new position in shares of Treace Medical Concepts in the second quarter valued at $28,000. 40.96% of the stock is currently owned by hedge funds and other institutional investors.

Treace Medical Concepts Company Profile

(Get Rating)

Treace Medical Concepts, Inc, an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.

Further Reading

Insider Buying and Selling by Quarter for Treace Medical Concepts (NASDAQ:TMCI)

Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.